These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 18468430)
1. [Life threatening drug-induced hyperkaliemia--case report]. Konopa J; Bullo B; Rutkowski B Pol Arch Med Wewn; 2006 Mar; 115(3):238-42. PubMed ID: 18468430 [TBL] [Abstract][Full Text] [Related]
2. [Late drug-induced hyperkalemia in a patient with congestive heart failure]. Konopa J; Bułło B; Rutkowski B Przegl Lek; 2005; 62(7):732-3. PubMed ID: 16463712 [TBL] [Abstract][Full Text] [Related]
3. [Drug-related hyperkalemia resulted from spironolactone and angiotensin converting enzyme inhibitors therapy]. Dutka M; Dzielski T; Wojciechowska J; Heller L; Trybus M Pol Merkur Lekarski; 1999 Aug; 7(38):69-70. PubMed ID: 10522422 [TBL] [Abstract][Full Text] [Related]
4. Life-threatening hyperkalemia associated with captopril administration. Doman K; Perlmutter JA; Muhammedi M; Puschett JB South Med J; 1993 Nov; 86(11):1269-72. PubMed ID: 8235783 [TBL] [Abstract][Full Text] [Related]
5. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure]. Fuster D; Frey FJ; Ferrari P Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849 [TBL] [Abstract][Full Text] [Related]
6. Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone. Erden I; Yalcin S; Ozhan H Kardiol Pol; 2010 Sep; 68(9):1043-5; discussion 1046. PubMed ID: 20859899 [TBL] [Abstract][Full Text] [Related]
7. Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort. Abbas S; Ihle P; Harder S; Schubert I Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):406-13. PubMed ID: 25683504 [TBL] [Abstract][Full Text] [Related]
9. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania. Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676 [TBL] [Abstract][Full Text] [Related]
10. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305 [TBL] [Abstract][Full Text] [Related]
11. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Reardon LC; Macpherson DS Arch Intern Med; 1998 Jan; 158(1):26-32. PubMed ID: 9437375 [TBL] [Abstract][Full Text] [Related]
12. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA; JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895 [TBL] [Abstract][Full Text] [Related]
13. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294 [TBL] [Abstract][Full Text] [Related]
14. [Hyperkalemia during prolonged use of angiotensin II-converting enzyme inhibitors in end-stage renal insufficiency]. Mooser V; Fellay G; Regamey C Schweiz Med Wochenschr; 1992 Dec; 122(50):1927-9. PubMed ID: 1465596 [TBL] [Abstract][Full Text] [Related]
15. [Ineffective atrial pacing and cardiac arrest in a 80-year old woman with hyperkalemia]. Lelakowski J; Czunko A; Majewski J; Pasowicz M; Małecka B; Bednarek J Pol Merkur Lekarski; 2005 May; 18(107):566-7. PubMed ID: 16161957 [TBL] [Abstract][Full Text] [Related]
16. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone. Berry C; McMurray J Am J Med; 2001 Nov; 111(7):587. PubMed ID: 11705445 [No Abstract] [Full Text] [Related]
17. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis. Maddirala S; Khan A; Vincent A; Lau K Am J Med Sci; 2008 Oct; 336(4):330-5. PubMed ID: 18854676 [TBL] [Abstract][Full Text] [Related]
18. [Prospective observational study of angiotensin converting enzyme inhibitors-induced hyperkalemia in hospitalized patients with chronic renal failure]. Ben Mahmoud L; Ghozzi H; Kammoun K; Hakim A; Kharrat M; Ben Hmida M; Jarraya F; Sahnoun Z; Zeghal K; Hachicha J Nephrol Ther; 2013 Apr; 9(2):98-102. PubMed ID: 23022289 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Surabenjawong U; Thunpiphat N; Chatsiricharoenkul S; Monsomboon A J Med Assoc Thai; 2013 Aug; 96(8):905-10. PubMed ID: 23991595 [TBL] [Abstract][Full Text] [Related]
20. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Raebel MA Cardiovasc Ther; 2012 Jun; 30(3):e156-66. PubMed ID: 21883995 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]